We will spend the next grant period on epigenetic marks in lung cancer that will build on our previous work on unmasking promoter methylation (Aim 3). We will extend our promoter work to extensively study hypomethylated promoters with a subsequent increase in gene expression for incorporation into EDRN collaborations that focus on RNA or protein (Aim 2). We will assess global methylation status in lung cancer cell lines and primary lung tumors and use new tiled arrays to identify genome-wide regions of methylation (Aim 1). These studies will thus be complementary to our ongoing studies using pharmacologic unmasking and will allow direct comparison between genes methylated in tumors of unclear significance and those that are reactivated after 5-AZA treatment, suggesting a more functional role in tumor progression. Once identified, we will use the assays we developed including MSP and QMSP to test regions of promoter hypermethylation to develop measurable biomarkers. These assays will allow continuing to develop highly specific and sensitive tests to detect tumor cells in various bodily fluids such as serum, plasma, sputum, and BAL fluid for early detection and diagnosis. We have also designed a novel QD-FRET nanoprobe technology for detecting nucleic acids and an additional approach here will be to build these probes for specific methylation markers we discover and validate. The proposed integrated program has the ability to achieve this goal because it optimally applies existing investigator talent, achievement, and interest using the most promising current research directions in epigenetics.
This proposal will comprehensively identify a variety of epigenetic markers in lung cancer. All the proposed aims are unite around the common research goal of generating and applying new molecular markers for the eariy detection and diagnosis of lung cancer. In this way, the morbidity and mortality of this deadly disease may be diminished by eariy and timely detection with appropriate therapy.
|Izumchenko, Evgeny; Sun, Kai; Jones, Sian et al. (2015) Notch1 mutations are drivers of oral tumorigenesis. Cancer Prev Res (Phila) 8:277-86|
|Guerrero-Preston, Rafael; Ogawa, Takenori; Uemura, Mamoru et al. (2014) Cold atmospheric plasma treatment selectively targets head and neck squamous cell carcinoma cells. Int J Mol Med 34:941-6|
|Brebi, Priscilla; Maldonado, Leonel; Noordhuis, Maartje G et al. (2014) Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. Epigenetics 9:308-17|
|Izumchenko, Evgeny; Chang, Xiaofei; Michailidi, Christina et al. (2014) The TGF?-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 74:3995-4005|
|Maldonado, Leonel; Brait, Mariana; Loyo, Myriam et al. (2014) GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. J Urol 192:1542-8|
|Guerrero-Preston, Rafael; Hadar, Tal; Ostrow, Kimberly Laskie et al. (2014) Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol Rep 32:505-12|
|Guerrero-Preston, Rafael; Michailidi, Christina; Marchionni, Luigi et al. (2014) Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics 9:1031-46|
|Guo, Mingzhou; Jia, Yan; Yu, Zhengtao et al. (2014) Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas. Discov Med 17:67-73|
|Brait, Mariana; Munari, Enrico; LeBron, Cynthia et al. (2013) Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. Cell Cycle 12:1058-70|
|Ili, Carmen Gloria; Brebi, Priscilla; Tapia, Oscar et al. (2013) Cellular FLICE-like inhibitory protein long form (c-FLIPL) overexpression is related to cervical cancer progression. Int J Gynecol Pathol 32:316-22|
Showing the most recent 10 out of 119 publications